1413373-77-9

Upstream product

• 54811-38-0 5-iodo-2-methylbenzoic?acid 
• 898566-17-1 (2-(4-fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene) 
• 110391-10-1 (4R,5S,6R)-4,5,6-tris(benzyloxy)-3-((benzyloxy)methyl)-2-cyclohexen-1-one 
• 115250-38-9 (1S)-(1(OH),2,4/1,3)-2,3,4-Tri-O-benzyl-1-C-<(benzyloxy)methyl>-5-oxo-1,2,3,4-cyclohexanetetrol 
• 108440-70-6 5-iodo-2-methylbenzoyl?chloride 
• 140926-87-0 3,4,5,7-Tetra-O-benzyl-1-deoxy-1-(dimethoxyphosphoryl)-α-D-gluco-2-heptulopyranose 
• 1413373-15-5 C₃₅H₃₆O₆ 
• 868159-57-3 C₃₅H₄₀O₆ 
• 115250-32-3 3,4,5,7-tetra-O-benzyl-1-deoxy-1-(dimethoxyphosphoryl)-D-xylo-2,6-heptodiulose 
• 4291-69-4 2,3,4,6-Tetra-O-benzyl-D-glucopyranose 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 115250-30-1 ((3S,4S,5R,6R)-3,4,5,7-Tetrakis-benzyloxy-2,6-dihydroxy-heptyl)-phosphonic acid dimethyl ester 
• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 1132832-75-7 (5-bromo-2-methylphenyl)[5-(p-fluorophenyl)thiophene-2-yl]methanone 

Downstream Products

• 1413373-80-4 2-(4-fluorophenyl)-5-(2-methyl-5-((3R,4R,5S,6S)-4,5,6-tris(benzyloxy)-3-(benzyloxymethyl)cyclohex-1-enyl)benzyl)thiophene 

Relevant academic research and scientific papers

A hypoglycemic compound and its preparation method and application

The invention discloses an efficient blood glucose reducing compound as well as a preparation and an application thereof. The structure of the compound disclosed by the invention is shown in a formula I, in the formula, R1, R2, R3 and R4 are defined in specification and claims. The invention further discloses the preparation method of the compound shown in the formula I. The compound shown in the formula I has an inhibiting activity to SGLT (Sodium-Glucose-Linked Transporter), and can be effectively used for preventing or treating diseased related to hyperglycemia.

FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS

The present invention relates to a compound of the following formula (I): as well as its process of preparation, pharmaceutical and cosmetics composition comprising it and use thereof, notably as an inhibitor of the sodium-dependent glucose co-transporter, such as SGLTl, SGLT2 and SGLT3, in particular in the treatment or prevention of diabetes, and more particularly type-II diabetes, diabetes-related complications, such as arthritis of the lower extremities, cardiac infarction, renal insufficiency, neuropathy or blindness, hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X syndrome and arteriosclerosis, as well as for its use as an anticancer, anti-infective, anti-viral, anti-thrombotic or anti- inflammatory drug, or for lightening, bleaching, depigmenting the skin, removing blemishes from the skin, particularly age spots and freckles, or preventing pigmentation of the skin.